dc.contributor |
Landspítali |
dc.contributor.author |
Danielsen, Ragnar |
dc.date.accessioned |
2022-11-02T01:04:34Z |
dc.date.available |
2022-11-02T01:04:34Z |
dc.date.issued |
2021-05 |
dc.identifier.citation |
Danielsen , R 2021 , ' Tegund 2 sykursýki: vaxandi vandamál og nýjungar í lyfjameðferð ' , Læknablaðið , bind. 107 , nr. 5 , bls. 223 . https://doi.org/10.17992/lbl.2021.05.632 |
dc.identifier.issn |
0023-7213 |
dc.identifier.other |
63490725 |
dc.identifier.other |
1425c99c-fa19-4920-bd4c-006560a1f26c |
dc.identifier.other |
33904829 |
dc.identifier.other |
85105833373 |
dc.identifier.uri |
https://hdl.handle.net/20.500.11815/3567 |
dc.format.extent |
1201952 |
dc.format.extent |
223 |
dc.language.iso |
is |
dc.relation.ispartofseries |
Læknablaðið; 107(5) |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Hjartalæknisfræði |
dc.subject |
Diabetes Mellitus, Type 2 |
dc.subject |
Humans |
dc.subject |
Pharmaceutical Preparations |
dc.title |
Tegund 2 sykursýki: vaxandi vandamál og nýjungar í lyfjameðferð |
dc.title.alternative |
Diabetesan increasing problem and novel drug treatment |
dc.type |
/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/editorial |
dc.identifier.doi |
10.17992/lbl.2021.05.632 |
dc.contributor.department |
Hjarta- og æðaþjónusta |